Isomorphic Labs

Isomorphic Labs is a British artificial intelligence company headquartered in London, with a singular focus on transforming drug discovery. Founded by Demis Hassabis, the mind behind DeepMind, the company operates under the Alphabet Inc. umbrella, having been spun out of DeepMind in 2021. Hassabis, who also leads DeepMind, serves as CEO of Isomorphic Labs, bringing his visionary approach to a new frontier: pharmaceuticals.

The company's core technology leverages AlphaFold, a groundbreaking AI system developed at DeepMind that predicts protein structures with remarkable accuracy. By applying this capability to drug research, Isomorphic Labs aims to identify new pathways for drug delivery and accelerate the development of treatments. The company's incorporation in February 2021 and public announcement in November 2021 signaled a bold step into the intersection of AI and biology, positioning it as a key player in the race to revolutionize medicine. While still in its early stages, Isomorphic Labs has attracted attention for its ambitious mission and the pedigree of its leadership, though specific financial details and product pipelines remain under wraps.

Isomorphic Labs is building a platform that extends beyond mere protein structure prediction. The team, many of whom contributed to AlphaFold, is working to model fundamental mechanisms of life, from molecular interactions to cellular pathways. Their goal is to find new biology at scale across every therapeutic modality, from small molecules to biologics. At conferences like ICML, researchers from the company have presented methods to generalise drug discovery across different treatment types, showing a commitment to pushing the boundaries of what AI can do in medicine.

The company's brand identity, crafted with the design firm Pentagram, reflects its scientific ambition. The name "Isomorphic" points to the mathematical idea of structural correspondence, mirroring the company's mission to map biological structures to therapeutic interventions. This thoughtful branding, combined with an active presence on social media and a steady recruitment drive, suggests a company that is as deliberate about its public image as it is about its research. [edit]